Addex Therapeutics (ADXN) Operating Expenses (2018 - 2025)

Addex Therapeutics has disclosed Operating Expenses across 8 years of filings, most recently posting $6.5 million for Q4 2025.

• Operating Expenses for Q4 2025 came in at $6.5 million, down 3.5% year-over-year; the trailing twelve-month figure through Dec 2025 was $3.9 million (up 6.31% YoY), and the FY2025 annual result was $3.6 million, changed 0.28% from the prior year.
• Operating Expenses came in at $6.5 million for Q4 2025 at Addex Therapeutics, up from -$932300.4 in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $35.4 million in Q4 2021 to a low of -$7.6 million in Q2 2022.
• The 5-year median for Operating Expenses is -$1.0 million (2023), against an average of $2.2 million.
• Peak annual rise in Operating Expenses reached 85.54% in 2023, while the deepest fall reached 75.13% in 2023.
• Addex Therapeutics' Operating Expenses stood at $35.4 million in 2021, then decreased by 12.46% to $31.0 million in 2022, then slumped by 75.13% to $7.7 million in 2023, then declined by 12.86% to $6.7 million in 2024, then dropped by 3.5% to $6.5 million in 2025.
• The last three Operating Expenses figures came in at $6.5 million (Q4 2025), -$932300.4 (Q3 2025), and -$929197.3 (Q2 2025), per Business Quant data.